LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension
The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood p...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2016-04, Vol.18 (4), p.308-314 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 314 |
|---|---|
| container_issue | 4 |
| container_start_page | 308 |
| container_title | The journal of clinical hypertension (Greenwich, Conn.) |
| container_volume | 18 |
| creator | Kario, Kazuomi Tamaki, Yuko Okino, Naoko Gotou, Hiromi Zhu, Min Zhang, Jack |
| description | The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood pressure (DBP) ≥110 mm Hg received LCZ696 200 mg. If blood pressure was uncontrolled, the LCZ696 dose was increased to 400 mg after 2 weeks (if there were no safety concerns; n=32), followed by an optional addition of another antihypertensive drug (except angiotensin receptor blocker and angiotensin‐converting enzyme inhibitor) after 4 weeks (n=21). Reductions in office SBP/DBP (baseline, 173.4 mm Hg/112.4 mm Hg) and pulse pressure (baseline, 61.0 mm Hg) at week 8 were 35.3/22.1 mm Hg and 13.2 mm Hg, respectively. The overall incidence of adverse events was 48.6% with no reports of dizziness, hypotension, or angioedema. The LCZ696‐based regimen was generally well‐tolerated and could present a treatment option for severe hypertension in Asian patients especially in reducing SBP and pulse pressure. |
| doi_str_mv | 10.1111/jch.12667 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8032009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1780139955</sourcerecordid><originalsourceid>FETCH-LOGICAL-p3417-eed2a61fe9c89d0e66822052854754b2cb1dd9a800e058c2851cdeac498caff53</originalsourceid><addsrcrecordid>eNpVUcFuEzEUtFARLYFDfwD5yKHb2t611-aAFK3aJlUECIqQuFiO96XryvFu15vS3PgADnwjX1InaSvqgz2aN5p51iB0SMkxTefk2jbHlAlRvkAHtOQ0K2kp9hLmrMhEYvbR6xivCeF5rsgrtM9EQZii8gD9mVU_hRJH2OAz18fh3--_LqSr8iZGPA5Xrh0gRBfwV7DQDW2fhp-g651fb9hpaNzcJfoDvmxg54Er74KzxuPTuw56B8ECTtovZkh4iPiHGxr8DW6hBzxZJ8k2og1v0MuF8RHePrwj9P3s9LKaZLPP59NqPMu6vKBlBlAzI-gClJWqJiCEZIxwJnlR8mLO7JzWtTKSECBc2sRTW4OxhZLWLBY8H6GPO99uNV9CbdNSvfE6fWpp-rVujdPPJ8E1-qq91ZLkjBCVDN4_GPTtzQrioJcuWvDeBGhXUdNSEporxTdZ7_7Pegp5rCAJTnaCX87D-mlOid50q1O3etutvqgmW5DfA-Spm_U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780139955</pqid></control><display><type>article</type><title>LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension</title><source>MEDLINE</source><source>Wiley Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Kario, Kazuomi ; Tamaki, Yuko ; Okino, Naoko ; Gotou, Hiromi ; Zhu, Min ; Zhang, Jack</creator><creatorcontrib>Kario, Kazuomi ; Tamaki, Yuko ; Okino, Naoko ; Gotou, Hiromi ; Zhu, Min ; Zhang, Jack</creatorcontrib><description>The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood pressure (DBP) ≥110 mm Hg received LCZ696 200 mg. If blood pressure was uncontrolled, the LCZ696 dose was increased to 400 mg after 2 weeks (if there were no safety concerns; n=32), followed by an optional addition of another antihypertensive drug (except angiotensin receptor blocker and angiotensin‐converting enzyme inhibitor) after 4 weeks (n=21). Reductions in office SBP/DBP (baseline, 173.4 mm Hg/112.4 mm Hg) and pulse pressure (baseline, 61.0 mm Hg) at week 8 were 35.3/22.1 mm Hg and 13.2 mm Hg, respectively. The overall incidence of adverse events was 48.6% with no reports of dizziness, hypotension, or angioedema. The LCZ696‐based regimen was generally well‐tolerated and could present a treatment option for severe hypertension in Asian patients especially in reducing SBP and pulse pressure.</description><identifier>ISSN: 1524-6175</identifier><identifier>ISSN: 1751-7176</identifier><identifier>EISSN: 1751-7176</identifier><identifier>DOI: 10.1111/jch.12667</identifier><identifier>PMID: 26402918</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><subject>Aged ; Aminobutyrates - administration & dosage ; Angiotensin Receptor Antagonists - administration & dosage ; Biphenyl Compounds ; Blood Pressure - drug effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Combinations ; Female ; Follow-Up Studies ; Humans ; Hypertension - drug therapy ; Hypertension - physiopathology ; Male ; Middle Aged ; Neprilysin - antagonists & inhibitors ; Original Paper ; Original Papers ; Severity of Illness Index ; Tetrazoles - administration & dosage ; Time Factors ; Treatment Outcome ; Valsartan</subject><ispartof>The journal of clinical hypertension (Greenwich, Conn.), 2016-04, Vol.18 (4), p.308-314</ispartof><rights>2015 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032009/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032009/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26402918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Tamaki, Yuko</creatorcontrib><creatorcontrib>Okino, Naoko</creatorcontrib><creatorcontrib>Gotou, Hiromi</creatorcontrib><creatorcontrib>Zhu, Min</creatorcontrib><creatorcontrib>Zhang, Jack</creatorcontrib><title>LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension</title><title>The journal of clinical hypertension (Greenwich, Conn.)</title><addtitle>J Clin Hypertens (Greenwich)</addtitle><description>The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood pressure (DBP) ≥110 mm Hg received LCZ696 200 mg. If blood pressure was uncontrolled, the LCZ696 dose was increased to 400 mg after 2 weeks (if there were no safety concerns; n=32), followed by an optional addition of another antihypertensive drug (except angiotensin receptor blocker and angiotensin‐converting enzyme inhibitor) after 4 weeks (n=21). Reductions in office SBP/DBP (baseline, 173.4 mm Hg/112.4 mm Hg) and pulse pressure (baseline, 61.0 mm Hg) at week 8 were 35.3/22.1 mm Hg and 13.2 mm Hg, respectively. The overall incidence of adverse events was 48.6% with no reports of dizziness, hypotension, or angioedema. The LCZ696‐based regimen was generally well‐tolerated and could present a treatment option for severe hypertension in Asian patients especially in reducing SBP and pulse pressure.</description><subject>Aged</subject><subject>Aminobutyrates - administration & dosage</subject><subject>Angiotensin Receptor Antagonists - administration & dosage</subject><subject>Biphenyl Compounds</subject><subject>Blood Pressure - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neprilysin - antagonists & inhibitors</subject><subject>Original Paper</subject><subject>Original Papers</subject><subject>Severity of Illness Index</subject><subject>Tetrazoles - administration & dosage</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Valsartan</subject><issn>1524-6175</issn><issn>1751-7176</issn><issn>1751-7176</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUcFuEzEUtFARLYFDfwD5yKHb2t611-aAFK3aJlUECIqQuFiO96XryvFu15vS3PgADnwjX1InaSvqgz2aN5p51iB0SMkxTefk2jbHlAlRvkAHtOQ0K2kp9hLmrMhEYvbR6xivCeF5rsgrtM9EQZii8gD9mVU_hRJH2OAz18fh3--_LqSr8iZGPA5Xrh0gRBfwV7DQDW2fhp-g651fb9hpaNzcJfoDvmxg54Er74KzxuPTuw56B8ECTtovZkh4iPiHGxr8DW6hBzxZJ8k2og1v0MuF8RHePrwj9P3s9LKaZLPP59NqPMu6vKBlBlAzI-gClJWqJiCEZIxwJnlR8mLO7JzWtTKSECBc2sRTW4OxhZLWLBY8H6GPO99uNV9CbdNSvfE6fWpp-rVujdPPJ8E1-qq91ZLkjBCVDN4_GPTtzQrioJcuWvDeBGhXUdNSEporxTdZ7_7Pegp5rCAJTnaCX87D-mlOid50q1O3etutvqgmW5DfA-Spm_U</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Kario, Kazuomi</creator><creator>Tamaki, Yuko</creator><creator>Okino, Naoko</creator><creator>Gotou, Hiromi</creator><creator>Zhu, Min</creator><creator>Zhang, Jack</creator><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201604</creationdate><title>LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension</title><author>Kario, Kazuomi ; Tamaki, Yuko ; Okino, Naoko ; Gotou, Hiromi ; Zhu, Min ; Zhang, Jack</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p3417-eed2a61fe9c89d0e66822052854754b2cb1dd9a800e058c2851cdeac498caff53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aminobutyrates - administration & dosage</topic><topic>Angiotensin Receptor Antagonists - administration & dosage</topic><topic>Biphenyl Compounds</topic><topic>Blood Pressure - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neprilysin - antagonists & inhibitors</topic><topic>Original Paper</topic><topic>Original Papers</topic><topic>Severity of Illness Index</topic><topic>Tetrazoles - administration & dosage</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Valsartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kario, Kazuomi</creatorcontrib><creatorcontrib>Tamaki, Yuko</creatorcontrib><creatorcontrib>Okino, Naoko</creatorcontrib><creatorcontrib>Gotou, Hiromi</creatorcontrib><creatorcontrib>Zhu, Min</creatorcontrib><creatorcontrib>Zhang, Jack</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kario, Kazuomi</au><au>Tamaki, Yuko</au><au>Okino, Naoko</au><au>Gotou, Hiromi</au><au>Zhu, Min</au><au>Zhang, Jack</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension</atitle><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle><addtitle>J Clin Hypertens (Greenwich)</addtitle><date>2016-04</date><risdate>2016</risdate><volume>18</volume><issue>4</issue><spage>308</spage><epage>314</epage><pages>308-314</pages><issn>1524-6175</issn><issn>1751-7176</issn><eissn>1751-7176</eissn><abstract>The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood pressure (DBP) ≥110 mm Hg received LCZ696 200 mg. If blood pressure was uncontrolled, the LCZ696 dose was increased to 400 mg after 2 weeks (if there were no safety concerns; n=32), followed by an optional addition of another antihypertensive drug (except angiotensin receptor blocker and angiotensin‐converting enzyme inhibitor) after 4 weeks (n=21). Reductions in office SBP/DBP (baseline, 173.4 mm Hg/112.4 mm Hg) and pulse pressure (baseline, 61.0 mm Hg) at week 8 were 35.3/22.1 mm Hg and 13.2 mm Hg, respectively. The overall incidence of adverse events was 48.6% with no reports of dizziness, hypotension, or angioedema. The LCZ696‐based regimen was generally well‐tolerated and could present a treatment option for severe hypertension in Asian patients especially in reducing SBP and pulse pressure.</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>26402918</pmid><doi>10.1111/jch.12667</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1524-6175 |
| ispartof | The journal of clinical hypertension (Greenwich, Conn.), 2016-04, Vol.18 (4), p.308-314 |
| issn | 1524-6175 1751-7176 1751-7176 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8032009 |
| source | MEDLINE; Wiley Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central |
| subjects | Aged Aminobutyrates - administration & dosage Angiotensin Receptor Antagonists - administration & dosage Biphenyl Compounds Blood Pressure - drug effects Dose-Response Relationship, Drug Double-Blind Method Drug Combinations Female Follow-Up Studies Humans Hypertension - drug therapy Hypertension - physiopathology Male Middle Aged Neprilysin - antagonists & inhibitors Original Paper Original Papers Severity of Illness Index Tetrazoles - administration & dosage Time Factors Treatment Outcome Valsartan |
| title | LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A44%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LCZ696,%20a%20First%E2%80%90in%E2%80%90Class%20Angiotensin%20Receptor%E2%80%90Neprilysin%20Inhibitor:%20The%20First%20Clinical%20Experience%20in%20Patients%20With%20Severe%20Hypertension&rft.jtitle=The%20journal%20of%20clinical%20hypertension%20(Greenwich,%20Conn.)&rft.au=Kario,%20Kazuomi&rft.date=2016-04&rft.volume=18&rft.issue=4&rft.spage=308&rft.epage=314&rft.pages=308-314&rft.issn=1524-6175&rft.eissn=1751-7176&rft_id=info:doi/10.1111/jch.12667&rft_dat=%3Cproquest_pubme%3E1780139955%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780139955&rft_id=info:pmid/26402918&rfr_iscdi=true |